Literature DB >> 22432994

Mortality risk stratification in severely anaemic Jehovah's Witness patients.

A M Beliaev1, R J Marshall, W Smith, J A Windsor.   

Abstract

The aim of this retrospective cohort study was to identify early risk factors of mortality and develop a mortality risk stratification instrument for severely anaemic Jehovah's Witness patients. It has been shown that Jehovah's Witness patients with the Auckland Anaemia Mortality Risk Score (Auckland AMRS) of 0 to 3 had 4% mortality, Auckland AMRS 4 to 5 32%, Auckland AMRS 6 to 7 50% and Auckland AMRS 8 and above 83%. It is concluded that the Auckland AMRS predicts mortality of severely anaemic Jehovah's Witness patients.
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22432994     DOI: 10.1111/j.1445-5994.2011.02699.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  Patterns of care in Jehovah's Witnesses patients with solid tumours and lymphoma.

Authors:  Rachael Chang Lee; Shawgi Sukumaran; Bogda Koczwara; Richard Woodman; Ganessan Kichenadasse; Amitesh Roy; Sina Vatandoust; Chris Karapetis
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-26

2.  High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.

Authors:  Andrei M Beliaev
Journal:  Blood Transfus       Date:  2013-03-19       Impact factor: 3.443

Review 3.  Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.

Authors:  Burak Zeybek; Andrew M Childress; Gokhan S Kilic; John Y Phelps; Luis D Pacheco; Michele A Carter; Mostafa A Borahay
Journal:  Obstet Gynecol Surv       Date:  2016-08       Impact factor: 2.347

4.  Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma.

Authors:  Alexandra Agapidou; Sofia Vakalopoulou; Theodosia Papadopoulou; Christina Chadjiaggelidou; Vasileia Garypidou
Journal:  Hematol Rep       Date:  2014-12-04

5.  The need for an artificial oxygen carrier for disasters and pandemics, including COVID-19.

Authors:  Richard B Weiskopf; Elon Glassberg; Nicole R Guinn; Michael F M James; Paul M Ness; Anthony E Pusateri
Journal:  Transfusion       Date:  2020-11-20       Impact factor: 3.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.